Neuren Pharmaceuticals Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • NEU

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $14.77
  • (As of Thursday Closing)

Neuren Pharmaceuticals General Information

Description

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 117 Camberwell Road, Hawthorn East
  • Suite 1.01
  • Melbourne, Victoria 3123
  • Australia
+61 (03)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
ASX
Corporate Office
  • 117 Camberwell Road, Hawthorn East
  • Suite 1.01
  • Melbourne, Victoria 3123
  • Australia
+61 (03)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuren Pharmaceuticals Stock Performance

As of 19-Nov-2026, Neuren Pharmaceuticals’s stock price is $14.77. Its current market cap is $1.87B with 127M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.77 $14.90 $7.69 - $16.99 $1.87B 127M 428K $0.11

Neuren Pharmaceuticals Financials Summary

As of 30-Jun-2026, Neuren Pharmaceuticals has a trailing 12-month revenue of $47.1M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,344,800 1,377,102 872,183 2,151,486
Revenue 47,089 41,647 140,644 153,927
EBITDA 10,441 17,264 113,408 132,387
Net Income 13,723 19,612 93,684 104,254
Total Assets 234,413 229,509 254,767 168,942
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neuren Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neuren Pharmaceuticals‘s full profile, request access.

Request a free trial

Neuren Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain i
Biotechnology
Melbourne, Australia
8 As of 2018

San Diego, CA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neuren Pharmaceuticals Competitors (26)

One of Neuren Pharmaceuticals’s 26 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
CuraSen Venture Capital-Backed San Carlos, CA
ZyVersa Therapeutics Formerly VC-backed Lighthouse Point, FL
Brainstorm Cell Therapeutics Corporation New York, NY
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 26 competitors. Get the full list »

Neuren Pharmaceuticals Patents

Neuren Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025903502-A0 Method of treatment Pending 07-Aug-2025
AU-2025901769-A0 Process for preparing cyclo-glycyl-l-2-allylproline Pending 09-May-2025
AU-2025901770-A0 Process for preparing cyclo-glycyl-l-2-allylproline Pending 09-May-2025
WO-2026232200-A1 Process for preparing cyclo-glycyl-l-2-allylproline Pending 09-May-2025
WO-2026232202-A1 Process for preparing cyclo-glycyl-l-2-allylproline Pending 09-May-2025
To view Neuren Pharmaceuticals’s complete patent history, request access »

Neuren Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuren Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Neuren Pharmaceuticals‘s full profile, request access.

Request a free trial

Neuren Pharmaceuticals Acquisitions (1)

Neuren Pharmaceuticals’s most recent deal was a Merger/Acquisition with Hamilton Pharmaceuticals for . The deal was made on 15-Oct-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Hamilton Pharmaceuticals 15-Oct-2007 Merger/Acquisition Drug Discovery
To view Neuren Pharmaceuticals’s complete acquisitions history, request access »

Neuren Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Neuren Pharmaceuticals’s complete esg history, request access »

Neuren Pharmaceuticals FAQs

  • When was Neuren Pharmaceuticals founded?

    Neuren Pharmaceuticals was founded in 2001.

  • Where is Neuren Pharmaceuticals headquartered?

    Neuren Pharmaceuticals is headquartered in Melbourne, Australia.

  • What is the size of Neuren Pharmaceuticals?

    Neuren Pharmaceuticals has 8 total employees.

  • What industry is Neuren Pharmaceuticals in?

    Neuren Pharmaceuticals’s primary industry is Biotechnology.

  • Is Neuren Pharmaceuticals a private or public company?

    Neuren Pharmaceuticals is a Public company.

  • What is Neuren Pharmaceuticals’s stock symbol?

    The ticker symbol for Neuren Pharmaceuticals is NEU.

  • What is the current stock price of Neuren Pharmaceuticals?

    As of 19-Nov-2026 the stock price of Neuren Pharmaceuticals is $14.77.

  • What is the current market cap of Neuren Pharmaceuticals?

    The current market capitalization of Neuren Pharmaceuticals is $1.87B.

  • What is Neuren Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Neuren Pharmaceuticals is $47.1M.

  • Who are Neuren Pharmaceuticals’s competitors?

    ACADIA Pharmaceuticals, CuraSen, ZyVersa Therapeutics, Brainstorm Cell Therapeutics, and Capricor Therapeutics are some of the 26 competitors of Neuren Pharmaceuticals.

  • What is Neuren Pharmaceuticals’s annual earnings per share (EPS)?

    Neuren Pharmaceuticals’s EPS for 12 months was $0.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process